scholarly journals Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase Ib trial evaluating topotecan by convection-enhanced delivery

2014 ◽  
Vol 1 (3) ◽  
pp. 94-100 ◽  
Author(s):  
Jennifer A. Oberg ◽  
Amie N. Dave ◽  
Jeffrey N. Bruce ◽  
Stephen A. Sands
Keyword(s):  
Quality Of Life ◽  
Disease Progression ◽  
Malignant Gliomas ◽  
Reliable Change Index ◽  
Response To Treatment ◽  
Neurocognitive Functioning ◽  
Convection Enhanced Delivery ◽  
Phase Ib ◽  
The Impact

Abstract Background Malignant gliomas are highly proliferative, invasive tumors that are resistant to conventional treatment, and disease progression is often accompanied by physical and mental debilitation. Neurocognitive functioning (NCF) and quality of life (QoL) were evaluated as part of a prospective phase Ib dose-escalation study of topotecan by convection-enhanced delivery (CED) for adult patients with recurrent malignant gliomas. Methods Sixteen patients were enrolled, and NCF and QoL were evaluated using the Cognitive Stability Index and SF-36 at baseline and monthly for 4 months post treatment. Descriptive analyses included the reliable change index for serial evaluations and correlations for associations between outcome variables and age, tumor volume, total topotecan dose, and treatment effect. Results Individual classifications of response to treatment indicated that a majority of patients reported stable scores over the follow-up period. Demographic and treatment-related variables were not associated with outcomes. Baseline processing speed scores were invalid for 6 subjects. Higher rates of valid scores were observed on subsequent administrations. Conclusions As the first study to use CED of any kind to evaluate the impact of CED on NCF or QoL, there was no evidence of severe detriment to either outcome. Long-term evaluation is necessary to track changes in NCF and QoL related to disease progression. Invalid scores suggest that computer-based assessments may not be suitable for all patients with malignant gliomas, especially those with cognitive deficits secondary to their disease. Future trials should include a wider range of sensitive measures to assess the impact of CED on patient NCF and QoL.

A Pilot Study on Educational Workshops for Caregivers of Patients with Brain Tumors Called AGAPE Showed its Feasibility and the Maintain Caregiver’s Quality of Life Despite Patient’s Disease Progression.

2021 ◽  
Author(s):  
Héloïse Bourien ◽  
Elodie Pelotte ◽  
Aurélie Thébault ◽  
Claire Larible-Lefort ◽  
Frédérique Lebrun ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Brain Tumors ◽  
Disease Progression ◽  
Adjuvant Treatment ◽  
Progressive Disease ◽  
Level Of Satisfaction ◽  
The Impact ◽  
Very High

Abstract Background Several studies have highlighted the difficulties faced by caregivers of patients with brain tumors. We created the educational workshops called AGAPE. Their aim is to explain precisely the medical aspects of brain tumors, describe resources available, and allow a moment of exchange between caregivers. Purpose To evaluate outcomes of AGAPE. Methods This was an observational uncontrolled pilot study. Feasibility was evaluated by the caregivers’ attendance of the 2 theoretical scheduled sessions and their satisfaction. Additional outcomes were the percentage of caregivers in favour of AGAPE sustainability and the impact on their quality of life according to CarGOQoL questionnaires (Caregiver Oncology Quality of Life) between baseline before the first workshop and after the last one. Results From February 2015 to March 2019, 12 three-month sessions were organized allowing 87 caregivers to participate. 84% of caregivers attended at least 2 theoretical sessions, the level of satisfaction was very high, and all caregivers were in favor of AGAPE sustainability. 36 caregivers submitted completed questionnaires at baseline and after the last workshop attended, separated by more than 2 months. The first workshop took place mostly during or after the adjuvant treatment of their loved ones. Two-thirds of their loved ones had a progressive disease after the first workshop and 21 died. Caregivers’ quality of life was stable between the first and last attended workshop. Conclusion Our study showed that AGAPE helped to maintain caregiver’s quality of life despite patient’s disease progression and its feasibility. Moreover, AGAPE may easily be run in other hospitals.

Effect of a Complementary/Integrative Medicine Treatment Program on Taxane-Induced Peripheral Neuropathy: A Brief Report

2018 ◽  
Vol 28 (5) ◽  
pp. 1045-1049 ◽  
Author(s):  
Eran Ben-Arye ◽  
Yaron River ◽  
Yael Keshet ◽  
Ofer Lavie ◽  
Pesi Israeli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peripheral Neuropathy ◽  
Integrative Medicine ◽  
Gynecological Cancer ◽  
Response To Treatment ◽  
Free Text ◽  
Short Term ◽  
Moderate Improvement ◽  
The Impact

ObjectivePeripheral neuropathy is a common complication of cancer treatment impairing quality of life and function. This study explored the impact of a complementary and integrative medicine (CIM) program on taxane-induced peripheral neuropathy (TIPN).Materials and MethodsTaxane-treated female patients with breast and gynecological cancer reporting TIPN-related symptoms were referred to an integrative physician, followed by patient-tailored CIM treatments (acupuncture with/without other modalities). Assessment of study outcomes at 6 to 12 weeks was conducted using the Measure Yourself Concerns and Wellbeing, which documented free-text narratives about patients’ experience during the CIM treatment process. Content was analyzed using ATLAS.Ti software.ResultsOf the 125 patients treated with taxanes, 69 had been referred for CIM treatment of TIPN-associated symptoms. Multidisciplinary narrative analysis identified 2 groups of CIM-treated patients: those with an apparently moderate improvement in symptoms (n = 35) and those with either only an apparent mild or no improvement at all. For 10 patients, assessment of their response to treatment was unclear. The 2 identified groups had similar demographic, cancer-related, and quality of life–related parameters at baseline. Content analysis of patients with an apparent moderate improvement suggested a short-term (24–48 hours) effect with acupuncture treatment, either alone or combined with manual, mind-body, and anthroposophic music therapies. Symptoms showing improvement included paresthesia and numbness.ConclusionsAcupuncture and other CIM therapies may result in a short-term and transitory reduction in TIPN-related symptoms.

A qualitative analysis of the impact of Carboplatin AUC 10 on physical, work functioning, and bone marrow toxicity, in patients with metastatic seminoma: A single centre experience.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 558-558 ◽  
Author(s):  
Marina Milic ◽  
Anand Sharma ◽  
Andrew Gogbashian ◽  
Annette Hawkins ◽  
Gordon J. S. Rustin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Response To Treatment ◽  
Physical Work ◽  
Bone Marrow Toxicity ◽  
Average Dose ◽  
Long Term Treatment ◽  
Grade 3 ◽  
The Impact

558 Background: We studied the efficacy, safety and tolerability of dose dense Carboplatin AUC10 chemotherapy and explored the HRQoL (health-related quality of life) in metastatic seminoma patients receiving this regimen. Methods: 46 patients with metastatic seminoma treated with Carboplatin AUC10 were identified in our centre. Carboplatin dosing at AUC 10 was used and calculated based on Calvert formula and EDTA clearance. Treatment was administered as a single dose every 21 days for 3 or 4 cycles. Response to treatment was determined by radiological imaging and serum tumour markers. Toxicities were evaluated using the CTCAE Version 4.0. Quality of life (QOL) and long-term treatment related toxicities were assessed post treatment using a self-designed telephonic questionnaire consisting of 4 questions about toxicity, which included- hair loss, hearing impairment, days absence from work and neuropathy. Results: Clinical characteristics are as follows: median age 44 (range 26-77), 34 patients had stage II and 12 stage III seminoma; average dose of carboplatin administered was 1240mg per cycle. 4.3% patients received 2, 87% 3 and 8.7.% 4 cycles of chemotherapy. 93% of patients achieved a complete remission (CR), 4 (all stage IIC) patients required a fourth cycle of chemotherapy, 2 undergoing RPLND and 2 watchful waiting. There was no disease relapse at median follow-up of 27.5 (range 4-84) months. 13 patients (28%) had grade 3 and 2 (4%) grade 4 neutropenia, thirteen (28%) grade 3/4 thrombocytopenia, Nine (19.5%) patients required prophylactic filgrastim. Commonest non-heamatological toxicities were fatigue in 28 (50%) and nausea 14(28%) patients. QOL data was available for 35/46 (76%) of patients. 40/46 (87%) patients had no residual tinnitus, one had residual grade 1 peripheral neuropathy. Eight patients continued to work throughout treatment, 16(45%) took < 5 days off work during chemotherapy, 4 took 5 to 21 days, 13 > 21 days, two were retired. Conclusions: Carbo AUC10 is a safe and effective treatment. Our results suggest the lack of negative impact of Carbo AUC10 on short and intermediate QOL without compromising treatment outcomes.

Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel

2006 ◽  
Vol 24 (4) ◽  
pp. 579-586 ◽  
Author(s):  
Elfriede R. Greimel ◽  
Vesna Bjelic-Radisic ◽  
Jacobus Pfisterer ◽  
Felix Hilpert ◽  
Fedor Daghofer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Randomized Study ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Response To Treatment ◽  
Free Survival ◽  
The Impact

Purpose The objective of this study was to compare the quality of life (QoL) of ovarian cancer patients treated with paclitaxel/carboplatin (TC) versus paclitaxel/cisplatin (PT) and to determine the impact of treatment toxicity on the various QoL domains. Patients and Methods In this phase III trial, 798 patients with ovarian cancer stages IIB-IV were randomly assigned to receive TC or PT. The primary end point was progression-free survival; secondary end points included toxicity, QoL, and response to treatment. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 before treatment, within 3 days before the second and the fourth chemotherapy cycle, and 3 weeks after completion of chemotherapy. Results Previously reported data showed that patients undergoing TC or PT did not differ in progression-free survival and overall survival. However, the TC arm was superior, indicating a better overall QoL compared with the PT arm. Controlling for toxicity and age, a significant treatment by assessment time interaction was found for four QoL functioning scales and three symptoms scales. Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm. Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT. Conclusion The TC regimen achieved better QoL outcomes compared with the PT regimen. Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4755-4755
Author(s):  
Timothy W Victor ◽  
Ishan Hirji ◽  
Ian Hicks ◽  
Jonathan Chapnick ◽  
Catherine Davis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Adherence ◽  
Research Funding ◽  
Oral Treatment ◽  
Chronic Phase ◽  
Daily Activities ◽  
Response To Treatment ◽  
Pilot Survey ◽  
The Impact

Abstract Abstract 4755 Background: While clinical outcomes among CML patients have shown great improvement with the development of TKIs, few studies have been conducted to assess the impact of CML and CML treatment from the perspective of CML patients. Information on CML treatment adherence and impact on quality of life (QoL) has been captured in the context of clinical trials with QoL being measured using generic measures. Very little is known about patient experience of CML and CML treatment in the real-world setting. Objective: To assess the impact of CML and CML treatment on daily productivity, quality of life and treatment adherence, from the patientâ|CE™s perspective. Method: In a pilot survey, twenty patients diagnosed with CML described their experiences in single 45 minute interviews conducted via telephone. Eligible patients included adults (>18 years) diagnosed with chronic phase CML and either currently on oral treatment for their CML or on drug holiday. Questions included in the pilot survey addressed overall treatment satisfaction, ease/burden of daily treatments and impact of treatment on daily activities. A preliminary analysis of 16 patients included in the pilot study was conducted. Results: Mean patient age was 52.9 years (SD = 12.6), 56.3% were male, averaged 3.1 years since diagnosis (SD = 3.1). Patientsâ|CE™ satisfaction with their oral CML treatment was high (mean 9.3 on a scale of 1 – 10, where 1 = not at all satisfied and 10 = very satisfied, SD = 1.3) among the 14 patients who provided a score. Perception of having a favorable response to treatment was also high (14/16). While patients reported good adherence to their treatment regimens, 9/16 patients mentioned missing doses of their CML treatment. Constitutional symptoms of treatment were reported as a daily occurrence by 50% of patients (8/16). Conclusion: In this pilot survey of the CML patientâ|CE™s perspective, high patient satisfaction with oral CML treatments was primarily attributable to a high overall response to treatment. Willingness to adapt to certain aspects of CML treatment was high given that treatment was perceived as being life-saving. Understanding factors which could minimize the impact on daily activities is important as new treatment options become available. Results from this pilot survey will inform the content of a self-administered questionnaire to include an expanded cohort of CML patients (n=300) within the US and Europe. Disclosures: Victor: Bristol-Myers Squibb Company: Research Funding. Hirji:Bristol Myers-Squibb: Employment. Hicks:Bristol-Myers Squibb Company: Research Funding. Chapnick:Bristol-Myers Squibb Company: Research Funding. Davis:Bristol Myers-Squibb: Employment.

Psychosocial outcomes 3 years after facial transplantation of a blind patient

2016 ◽  
Vol 33 (S1) ◽  
pp. S392-S392 ◽  
Author(s):  
G. Lemmens ◽  
H. Hendrickx ◽  
C. Poppe ◽  
N. Roche ◽  
P. Peeters ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Family Members ◽  
Psychosocial Outcomes ◽  
Dyadic Adjustment ◽  
Reliable Change Index ◽  
Facial Transplantation ◽  
The Impact

BackgroundTo date, psychosocial outcomes after facial transplantation are promising although long-term consequences, outcome of blind patients and the impact on family members are less well investigated. The aim of this study was to examine the long-term psychosocial of a blind patient and his partner 2 and 3 years after facial transplantation.MethodsDepressive and anxiety symptoms, hopelessness, coping, resilience, illness cognitions, marital support, dyadic adjustment, family functioning and quality of life of the patient and the partner were assessed before and 2 and 3 years after transplantation. Reliable change index (RCI) was further calculated to evaluate the magnitude of change.ResultsMost psychological, marital and family scores of both the patient and the partner remained within a normative and healthy range at follow-up. Resilience (RCI: 2.5 & 3.4 respectively), affective responsiveness (RCI: −4.1 & −3.2 respectively), physical quality of life (RCI: 8.7 & 7.2 respectively) and helplessness (RCI: −2.2 & −2.9 respectively) of the patient improved at 2 and 3 years follow-up. Further, dyadic cohesion (RCI: 2.4) of the patient improved at 2 years whereas marital depth (RCI: −2.0) of the partner decreased at 3 years.ConclusionsThe results of this study point to positive long-term psychosocial outcomes of a blind patient and his partner after facial transplantation. Further, they may underscore the importance of patient selection, social support and involvement of family members in treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals The impact of disease progression on perceived health status and quality of life of long-term cancer survivors

2009 ◽  
Vol 3 (3) ◽  
pp. 164-173 ◽  
Author(s):  
Melissa S. Y. Thong ◽  
Floortje Mols ◽  
Jan-Willem W. Coebergh ◽  
Jan A. Roukema ◽  
Lonneke V. van de Poll-Franse
Keyword(s):  
Quality Of Life ◽  
Health Status ◽  
Cancer Survivors ◽  
Disease Progression ◽  
Perceived Health ◽  
Perceived Health Status ◽  
The Impact

Self-Compassion and Quality of Life in Adults Who Stutter

2020 ◽  
Vol 29 (4) ◽  
pp. 2097-2108
Author(s):  
Robyn L. Croft ◽  
Courtney T. Byrd
Keyword(s):  
Quality Of Life ◽  
Social Connectedness ◽  
The Self ◽  
Future Research ◽  
Self Compassion ◽  
Adults Who Stutter ◽  
And Gender ◽  
Relationship Of ◽  
The Impact

Purpose The purpose of this study was to identify levels of self-compassion in adults who do and do not stutter and to determine whether self-compassion predicts the impact of stuttering on quality of life in adults who stutter. Method Participants included 140 adults who do and do not stutter matched for age and gender. All participants completed the Self-Compassion Scale. Adults who stutter also completed the Overall Assessment of the Speaker's Experience of Stuttering. Data were analyzed for self-compassion differences between and within adults who do and do not stutter and to predict self-compassion on quality of life in adults who stutter. Results Adults who do and do not stutter exhibited no significant differences in total self-compassion, regardless of participant gender. A simple linear regression of the total self-compassion score and total Overall Assessment of the Speaker's Experience of Stuttering score showed a significant, negative linear relationship of self-compassion predicting the impact of stuttering on quality of life. Conclusions Data suggest that higher levels of self-kindness, mindfulness, and social connectedness (i.e., self-compassion) are related to reduced negative reactions to stuttering, an increased participation in daily communication situations, and an improved overall quality of life. Future research should replicate current findings and identify moderators of the self-compassion–quality of life relationship.

Sign in / Sign up

Export Citation Format

Share Document